Dr Jeff Patton: Biosimilars and OCM

Jeff Patton, MD, president and CEO of Tennessee Oncology, discusses how biosimilars fit into the Oncology Care Model (OCM).
December 20, 2017


Do you see biosimilars having a role to play in [the Oncology Care Model, OCM]?

I do, and I don’t think we know yet how much cost savings will be involved with biosimilars, but we know it will be some. I think it will start around 15% and go up to 30%, maybe more. I think that the experience in Europe is 30%, 50% is high. The biosimilars are in a space that- so Genentech is biosimilars and is going to be impacted by biosimilars, so about a third of our spend is Genentech products, so if you reduce a third of your spend even by 10%, 15%, 20%, it’s a big number. So, we see biosimilars being very key to saving in OCM.


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.